Annual Biomarkers for Alzheimer’s Disease Summit
dateAugust 24-26, 2021
The Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to sharing innovations in identifying new novel biomarkers and solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement.
Back for its 2nd year, there will be a continued emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape, this industry-defining meeting delves into blood-based biomarkers, neuroinflammatory markers, and ample sharing of industry innovations in identifying novel biomarkers. Through open reflections and sharing competitive knowledge, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s disease.
Quanterix will be sponsoring this event with a virtual booth and the following presentation:
Innovations in Blood-Based Biomarkers for Alzheimer’s Disease
August 26, 2021 at 9:30am
Nicholas Ashton, PhD – Assistant Professor, Department of Psychiatry & Neurochemistry, University of Gothenburg
Introduction by Kevin Hrusovsky, CEO and Chairman, Quanterix
– Key features of assay development of plasma p-tau181 and p-tau231 on the Simoa platform: challenges but significant progress
– Overview of plasma p-tau across the AD continuum: Do different epitopes provide different information at different times?
– Head-to-head comparisons of p-tau plasma biomarkers
Share this page